Mirum Pharmaceuticals (MIRM) Amortization of Deferred Charges (2019 - 2026)

Mirum Pharmaceuticals' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $454000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges rose 4.85% year-over-year to $454000.0; the TTM figure through Mar 2026 stood at $1.8 million (up 4.76% YoY), while the FY2025 annual figure was $1.7 million, up 4.7% from the prior year.
• Amortization of Deferred Charges was $454000.0 for Q1 2026 at Mirum Pharmaceuticals, up from $436000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $454000.0 in Q1 2026 to a low of $307000.0 in Q2 2023.
• Historically, Amortization of Deferred Charges has averaged $414250.0 across 4 years, with a median of $420000.0 in 2024.
• Biggest YoY gain for Amortization of Deferred Charges was 32.57% in 2024; the steepest drop was 3.16% in 2024.
• A 4-year view of Amortization of Deferred Charges shows it stood at $399000.0 in 2023, then rose by 4.26% to $416000.0 in 2024, then rose by 4.81% to $436000.0 in 2025, then gained by 4.13% to $454000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $454000.0 (Q1 2026), $436000.0 (Q4 2025), and $443000.0 (Q3 2025), per Business Quant data.